Advancing the Care of Patients Living with EGPA Through Multidisciplinary, Patient-Focused
Antoine Azar, MD
Interim Division Director
Division of Allergy and Clinical Immunology
Associate Professor of Medicine
Johns Hopkins University
- Summarize the latest EGPA guidelines regarding early diagnosis and initiation of therapy considering the manifold possible presentations of EGPA
- List the signs and symptoms that may raise the index of suspicion for EGPA
- Select standard of care treatment and management options for different EGPA stages
patient-focused, multidisciplinary management tactics that can be implemented
into clinical care to improve care for patients with EGPA
Disclosures of Relevant Financial Relationships
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Antoine Azar, MD
Consultant, Advisor, or Speaker: Janssen, Pfizer, Takeda
Researcher: ArgenX, Grifols, X4
Leonard Calabrese, DO
Consultant, Advisor, or Speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galvani, GlaxoSmithKline, Genentech, Janssen, Regeneron, Sanofi/Genzyme, UCB
Anisha Dua, MD, MPH
Consultant, Advisor, or Speaker: AbbVie, Chemocentryx, Novartis, Sanofi
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Iridium planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Iridium. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this live material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For additional information about the accreditation of this activity,
please visit https://partnersed.com
1. View the presentation
2. Visit iridiumce.com/egpa-kra
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Credit Type: AMA
Estimated time to complete the activity: 1 hour